CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer

被引:1
|
作者
Sun, Qiqi [1 ]
Lei, Xiaoyong [1 ,2 ]
Yang, Xiaoyan [1 ,2 ]
机构
[1] Univ South China, Hengyang Med Coll, Sch Pharmaceut Sci, 28 Western Changsheng Rd, Hengyang 421001, Hunan, Peoples R China
[2] Univ South China, Hunan Prov Key Lab Tumor Microenvironm Respons Dru, 28 Western Changsheng Rd, Hengyang 421001, Hunan, Peoples R China
关键词
cancer; circRNA; HMGA2; miRNA; HEPATOCELLULAR-CARCINOMA PROGRESSION; CIRCULAR RNA; DRUG-RESISTANCE; BREAST-CANCER; HMGA2; PROLIFERATION; PROMOTES; MECHANISMS; METASTASIS; APOPTOSIS;
D O I
10.1016/j.pharmthera.2024.108711
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
High mobility group protein A2 (HMGA2) is widely recognized as a chromatin-binding protein, whose overexpression is observed in nearly all human cancers. It exerts its oncogenic effects by influencing various cellular processes such as the epithelial-mesenchymal transition, cell differentiation, and DNA damage repair. MicroRNA (miRNA) serves as a pivotal gene expression regulator, concurrently modulating multiple genes implicated in cancer progression, including HMGA2. It also serves as a significant biomarker for cancer. Circular RNA (circRNA) plays a crucial role in gene regulation primarily by sequestering miRNAs and impeding their ability to enhance the expression of other genes, including HMGA2. Increasingly, studies have underscored the vital role of miRNA/HMGA2 interactions in cancer. Given the significance of circRNA as an upstream regulatory mediator and the complexity of regulatory mechanisms, we hereby present a comprehensive overview of the pivotal role of circRNAs as upstream regulators of the miRNA//HMGA2 axis in human cancers. This insight may herald a novel direction for future cancer research. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Overexpression of HMGA2 as a prognostic indicator in breast cancer.
    Wang, Xiaochen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] HMGA2 ACTS AS A ceRNA TO STIMULATE LUNG CANCER METASTASIS
    不详
    CANCER DISCOVERY, 2014, 4 (02) : 141 - 141
  • [23] Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer
    Kong, Dequan
    Su, Guoqiang
    Zha, Lang
    Zhang, Hongyu
    Xiang, Jifeng
    Xu, Wei
    Tang, Yucheng
    Wang, Ziwei
    MEDICAL ONCOLOGY, 2014, 31 (08)
  • [24] Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer
    Dequan Kong
    Guoqiang Su
    Lang Zha
    Hongyu Zhang
    Jifeng Xiang
    Wei Xu
    Yucheng Tang
    Ziwei Wang
    Medical Oncology, 2014, 31
  • [25] HMGA2 Supports Cancer Hallmarks in Triple-Negative Breast Cancer
    Mansoori, Behzad
    Terp, Mikkel Green
    Mohammadi, Ali
    Pedersen, Christina Bog
    Ditzel, Henrik Jorn
    Baradaran, Behzad
    Gjerstorff, Morten Frier
    CANCERS, 2021, 13 (20)
  • [26] HMGA2 and p53 Axis in Evaluation of High Grade Endometrial Carcinoma
    Fischer, Jean
    Li, Yinuo
    Purdy, Jenna
    Wei, Jian-Jun
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 679 - 681
  • [27] HMGA2 regulation by miRNAs in cancer: Affecting cancer hallmarks and therapy response
    Hashemi, Mehrdad
    Rashidi, Mohsen
    Hushmandi, Kiavash
    ten Hagen, Timo L. M.
    Salimimoghadam, Shokooh
    Taheriazam, Afshin
    Entezari, Maliheh
    Falahati, Mojtaba
    PHARMACOLOGICAL RESEARCH, 2023, 190
  • [28] Regulation of HMGA2 and KRAS genes in epithelial ovarian cancer by miRNA hsa-let-7d-3p
    Gunel, Tuba
    Dogan, Berkcan
    Gumusoglu, Ece
    Hosseini, Mohammad Kazem
    Topuz, Samet
    Aydinli, Kilic
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (06) : 1321 - 1327
  • [29] Circ_0109046 Promotes the Progression of Endometrial Cancer via Regulating miR-136/HMGA2 Axis
    Shi, Yanping
    Jia, Li
    Wen, Hongli
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 10993 - 11003
  • [30] Human HMGA2 promoter is coregulated by a polymorphic dinucleotide (TC)-repeat
    Borrmann, L
    Seebeck, B
    Rogalla, P
    Bullerdiek, J
    ONCOGENE, 2003, 22 (05) : 756 - 760